

Patient Reported Outcomes Among Men with Advanced Prostate Cancer: Results from The IRONMAN Registry

Lorelei Mucci, Paul Villanti, Jake Vinson, Theresa Gold, Michael Jordan, Dana Rathkopf, Kim Chi, Tian Zhang, Pedro Barata, Heather Cheng, Mark Pomerantz, Robert Dreicer, Aijai Alva, Michael Ong, Elisabeth Heath, Deborah Enting, Young Whang, Sebastien Hotte, Anders Bjartell, Andre Fay, Aurelius Omlin, Ian Davis, Alicia Morgans, Kellie Paich, Justin McReynolds, Terry Hyslop, Travis Gerke, Daniel George, Philip Kantoff

Harvard TH Chan School of Public Health, the Movember Foundation, the Prostate Cancer Clinical Trials Consortium, the Prostate Cancer Clinical Trials Consortium, the Prostate Cancer Clinical Trials Consortium, Memorial Sloan Kettering Cancer Center, BC Cancer Agency, Duke University, Tulane University, University of Washington, Dana-Farber Cancer Institute, University of Virginia, University of Michigan, Ottawa Hospital Cancer Centre, Wayne State Karmanos Cancer Center, Guy's and St. Thomas' NHS Foundation Trust, University of North Carolina, Juravinski Cancer Centre, Skåne University Hospital, Centro de Pesquisa em Oncologia, Kantonsspital St. Gallen, Monash University, Northwestern University, the Movember Foundation, University of Washington, Duke University, Harvard TH Chan School of Public Health, Duke University, Memorial Sloan Kettering Cancer Center.

Background: Advanced prostate cancer is heterogeneous clinically, including metastatic hormone sensitive prostate cancer (mHSPC) and (M0)/(M1) castration resistant prostate cancer (CRPC). Little is known about the landscape of patient reported outcomes measures (PROMs) in men with newly diagnosed advanced prostate cancer.

Methods: This study leverages the global IRONMAN registry of men with advanced prostate cancer (<https://ironmanregistry.org/>). Men completed detailed PROMs questionnaires at study enrollment and every three months thereafter, either online using the TrueNTH ePROMs portal, on paper during clinic visits, or interview-style with research study staff. PROMs instruments included questions from EORTC QLQ-C30 v3, Brief Pain Inventory, FACT-FPSI 17, EPIC-26, as well as cognitive function and sleep quality. We focused on the baseline PROM responses on sleep, pain, depression, and overall quality of life for the first 500 IRONMAN participants accrued. The prevalence of individual PROMs was stratified by mHSPC and CRPC status, and also by race/ethnicity.

Results: Baseline PROMs completion compliance was 78%. During the prior week, 15% of mHSPC and 11% of CRPC patients reported quite a bit of pain. This pain level was more common among black (17%) than white (11%) men. Moreover, black men (18%) were more likely to report pain interfered with daily activities compared to white men (8%). The prevalence of depression was 6% among mHSPC and 3% among CRPC participants. Sleep problems were common at baseline, with 42% of mHSPC and 48% of CRPC men reporting difficulty falling asleep some or most of the time. The prevalence of sleep problems was similar in black and white men. On a scale of 1 (very poor) to 7 (excellent), 12% of mHSPC and 10% of CRPC men rated their overall quality of life in the past week as fair to poor; 52% of mHSPC and 58% rated their overall quality of life in the past week as very good to excellent. Black men (41%) were less likely to report good quality of life compared to white men (54%).

Conclusions: Men with newly diagnosed prostate cancer face a range of quality of life concerns, although over 50% of these men are positive about their quality of life. In future analyses, we will investigate the trajectory of PROMs over time, and investigate the influence of treatment regimens on quality of life. The IRONMAN registry addresses the unmet need for a comprehensive analysis of variations in the treatment of advanced prostate cancer and PROMs data.

Conflict of Interest:

DR - (Consulting/Advisory – Bayer, Genentech/Roche, Janssen Oncology, TRACON Pharma; Research Funding - AstraZeneca (Inst), Celgene (Inst), Ferring (Inst), Genentech/Roche (Inst), Janssen Oncology (Inst), Medivation (Inst), Millennium (Inst), Novartis (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), TRACON Pharma (Inst), Novartis (Inst), Pfizer (Inst).

KC - (Grant support and Honoraria – Astellas Pharma, Janssen, Sanofi, AstraZeneca, Bayer, Essa Phrma, Pfizer, Roche)

TZ - (Leadership – Capiro Biosciences (IFM); Stock/Other Ownership – Capiro Biosciences (IFM); Honoraria – Exelixis, Genentech/Roche; Consulting/Advisory – Bayer, Janssen, Genentech/Roche, Sanofi, Exelixis, AstraZeneca, Pfizer, Bristol-Myers Squibb, Foundation Medicine, Pharmacyclics, Amgen, Merck; Speakers' Bureau – Exelixis, Genentech/Roche, Genomic Health, Sanofi/Avenis; Research Funding – Janssen (Inst), Acerta Pharma (Inst), Pfizer (Inst), Merrimack (Inst), Stem CentRx (Inst), Novartis (Inst), OmniSeq (Inst), Personal Genome Diagnostics (Inst), Regeneron (Inst), Merck (Inst), Mirati Therapeutics (Inst); Patents/Royalties/Other IP - Circulating tumor cell novel capture by c-MET technology (Inst), Prochelators as Targeted Prodrugs for Prostate Cancer (Inst); Travel/Accommodating/Expenses – Acerta Pharma, Genomic Health, AstraZeneca)

PB - (Consulting/Advisory – Bristol-Myers Squibb, Pfizer, EMD Serono, Eisai; Speakers' Bureau – Caris; Research Funding – Genomic Health (Inst), BlueEarth Diagnosis (Inst); Travel/Accommodations/Expenses – Bristol-Myers Squibb, Pfizer, EMD Serono, Eisai)

HC - (Research Funding – Astellas (Inst), Clovis (Inst), Inovio (Inst), Janssen (Inst), Medivation (Inst), Sanofi (Inst)).

RD - (Consulting/Advisory – Pfizer, Astellas, Janssen, Vizuri, Seattle Genetics, Eisai, Genentech/Roche, AstraZeneca; Research Funding – Exelexis, Janssen, Merck, Genentech)

AA - (Consulting/Advisory – Merck, AstraZeneca; Research Funding - Clovis Oncology (Inst), Merck (Inst), Bristol-Myers Squibb (Inst), AstraZeneca (Inst), Bayer (Inst), Progenics (Inst), Janssen (Inst), Genentech (Inst), Esanik, Ionis (Inst), and Prometheus (Inst))

MO - (Consulting/Advisory – Janssen; Research Funding – AstraZeneca; Travel/Accommodations, Expenses – Janssen)

EH - (Honoraria – Bayer, Dendreon, Sanofi, Seattle Genetics ; Consulting/Advisory – Agensys; Speakers' Bureau – Sanofi; Research Funding – Takai Pharmaceuticals, Seattle Genetics, Agensys, Dendreon, Genentech/Roche, Millennium, Caris Life Sciences, Boehringer Ingelheim, GlaxoSmithKline, Merck Sharp & Dohme, Plexxikon, Corcept Therapeutics Fortis, Astellas Pharma, Medivation, AstraZeneca, Ignyta, Synta, Esanik, Zenith Epigenetics, Oncolys BioPharma, Curemeta, Bristol-Myers Squibb, eFFECTOR Therapeutics, Celldex, Inovio Pharmaceuticals, Celgene, Zenith Epigenetics, Merck; Other Relationship – Caris Centers of Excellence)

DE – (Honoraria – Pfizer, AstraZeneca, Merck Sharp & Dohme, EUSA Pharma; Consulting/Advisory - Pfizer, AstraZeneca, Merck Sharp & Dohme, EUSA Pharma; Travel/Accommodations/Expenses – Merck Sharp & Dohme, EUSA Pharma)

YW – (Research Funding – Clovis Oncology, Constellation)

SH – (Honoraria – Ipsen, Eisai, Bayer, Pfizer; Consulting/Advisory – Bayer, Janssen, Bristol-Myers Squibb, Pfizer, Eisai, Ipsen, Astellas, Merck, Roche; Research Funding – Janssen (Inst), Astellas (Inst), Bristol-

Myers Squibb (Inst), Merck (Inst), Astra Zeneca (Inst), Eisai (Inst), Roche (Inst), Ayala (Inst), Bayer (Inst)

AB – (Stock/Other ownership – WntResearch, LIDDS Pharma, Glactone Pharma; Consulting/Advisory – Astellas, Bayer, Janssen, Active Biotech, Incyte; Researching Funding – Ferring (Inst), Astellas (Inst), Bayer (Inst)

AO – (Consulting/Advisory - Astra Zeneca, Astellas, Bayer, Janssen, Molecular Partners, MSD, Pfizer, Roche, Sanofi Aventis; Speakers' Bureau – Bayer, Astellas; Research Funding – Janssen (Inst), Teva (Inst); Travel/Accommodations/Expenses - Astellas, Bayer, Janssen, Sanofi Aventis)

ID – (Research Funding – Astellas (Inst), EMD Serono (Inst), Hoffman La Roche (Inst), Eisai (Inst), Merck Sharpe & Dohme (Inst), Bayer (Inst), AstraZeneca (Inst), Gaurdant Health (Inst), Pfizer (Inst), Bristol-Myers Squibb (Inst), Aragon Pharmaceuticals (Inst); Patents/Royalties/Other IP- International Patent Application No: PCT /US2004/032147; Title: In vivo efficacy of NY-ESO-1 plus adjuvant. Inventors: J Cebon, I Davis, W Chen, S Green. Applicants: CSL Limited; Ludwig Institute For Cancer Research. Filed 30 September 2004. Published No. WO2005/032475; Issue Date: 14 April 2005. Status: AU2004277402 Granted 25 November 2010. Other jurisdictions under examination; Other relationship – ANZUP Cancer Trials Group (Director & Chair))

AM - (Honoraria – Astellas, Sanofi; Consulting/Advisory – Astellas, Bayer, Sanofi, AstraZeneca, Genentech, Seattle Genetics; Research Funding – Bayer (Inst) , Astellas (Inst); Travel/Accommodations/Expenses – Sanofi, Astellas)

TH – (Consulting/Advisory – Abbvie; Travel/Accommodations/Expenses – Abbvie)

DG - (Speakers' Beureau – Bayer, Exelixis, Sanofi; Honoraria – Bayer, EMD Serono, Exelixis, Ipsen, Michael J Hennessey Associates, Pfizer, Sanofi, UroGPO, UroToday; Consulting/Advisory – Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Capiro Biosciences, Flatiron Health, Janssen, Leidos Biomedical Research, Merck Sharp & Dohme, Michael J Hennessey Associates, Modra Pharmaceuticals B.V., Myovant Sciences, Inc., Nektar Therapeutics, Physician Education Resource, Pfizer, Sanofi, Vizuri Health Sciences, LLC.; Research Funding – Acerta Pharmaceuticals (Inst), Astellas (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Calithera (Inst), Exelixis (Inst), Janssen (Inst), Pfizer (Inst), Sanofi (Inst); Travel/Accommodations/Expenses – Bayer, Exelixis, Sanofi, UroToday; Other Relationship – American Association for Cancer Research (Senior Editor), Axess Oncology (Independent Contractor), Millennium Medical Publishing Clinical Advances in Hematology & Oncology (Co-Editor-in-Chief), NCI (Steering Committee)

PK - (Leadership – Context Therapeutics; Stock/Other Ownership – Placon, Druggability Technologies, Tarveda Therapeutics, Context Therapeutics, Seer; Consulting/Advisory – Baravian Nordic, Janssen, Merck, OncoCellMDX, Sanofi, Genetech/Roche, Tarveda Therapeutics, Druggability Technologies, Progenity, Thermo Fisher Scientific, Context Therapeutics, GE Healthcare, New England Research Institutes; Patents/Royalties/Other IP - Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality, Predicting and Treating Prostate Cancer, Methods for Predicting Likelihood of Responding to Treatment, Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality, Drug Combinations to Treat Cancer, Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent), Up-to-Date Royalties, Wolters Kluwer Royalties, Methods and Kits for Determining Sensitivity to Cancer Treatment, Composition and Methods for Screening and Diagnosis of Prostate Cancer; Travel/Accommodations/Expenses - Druggability Technologies)

Funding Acknowledgements: Movember Foundation, Astellas, AstraZeneca, Bayer, Sanofi-Genzyme, Amgen